Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).
Budesonide may leads to higher clinical response sensitivity analysis excluding Miehlke 2014 compared with placebo (low certainty).
Budesonide may leads to higher histological response sensitivity analysis excluding Miehlke 2014 compared with placebo (low certainty).
Budesonide may leads to higher maintenance of clinical response compared with placebo (low certainty).
It is very uncertain whether budesonide changes maintenance of histological response compared with placebo (very low certainty).
Budesonide showed no clear difference in adverse events compared with placebo (low certainty).
It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).
It is very uncertain whether budesonide changes serious adverse events compared with placebo (very low certainty).
Budesonide may leads to higher clinical response compared with mesalazine (low certainty).
Budesonide may leads to higher histological response compared with mesalazine (low certainty).
Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).
Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).
Budesonide may leads to higher clinical response compared with mesalazine (low certainty).
Budesonide may leads to higher histological response compared with mesalazine (low certainty).
Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).
Budesonide probably leads to lower clinical remission (ITT analysis) compared with mesalamine (moderate certainty).
Budesonide probably leads to lower endoscopic improvement Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in endoscopic remission (EI ≤ 1) compared with mesalamine (moderate certainty).
Budesonide probably leads to lower histologic remission Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in adverse events Gross 2011 compared with mesalamine (moderate certainty).